Lifecore Biomedical, Inc. \de\LFCR
What Lifecore Biomedical, Inc. \de\ does.
Lifecore Biomedical, Inc. and its subsidiaries (“Lifecore”, the “Company”, “we” or “us”), located in Chaska, Minnesota, is a fully integrated contract development and manufacturing organization (“CDMO”) that offers highly differentiated clinical and commercial capabilities in the development, cGMP manufacturing and aseptic filling of complex formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials and cartridges, across a wide variety of modalities. Lifecore has become a leading U.S. manufacturer of pharmaceutical-grade, non-animal-sourced hyaluronic acid (“HA”) using our proprietary, fermentation-based HA process that we developed in 1981. We manufacture HA in bulk form as well as for use in formulated and filled syringes and vials for our customers’ injectable products used in treating a broad spectrum of medical conditions and procedures, including ophthalmic and orthopedic applications. We have leveraged this expertise in HA fermentation, manufacturing and aseptic formulation and filling to also develop highly viscous non-HA-based sterile injectable products with our customers for multiple applications.
Lifecore’s product development service capabilities include analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation and production of materials for clinical studies. We also operate semi-automated Restricted Access Barrier Systems (“RABS”) and fully automated aseptic filling lines with isolators. These systems support efficient and safe aseptic processing of both synthetic and biologic drug products. Manufacturing takes place across our three cGMP facilities, where we produce FDA-approved (as defined below) commercial drug and device products. We have earned multiple certifications from regulatory agencies in Europe, Japan, Brazil and the International Organization for Standardization (“ISO”).
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $160.1M | $100.9M | $111.3M | $103.3M | $128.3M | $128.9M |
| Net income | -$38.2M | -$32.3M | -$116.7M | -$99.6M | $12.0M | -$38.7M |
| Free cash flow | -$29.3M | -$2.8M | -$48.8M | — | -$18.1M | -$13.6M |
More on LFCR.
- Lifecore Biomedical, Inc. \de\ summary
- Lifecore Biomedical, Inc. \de\ financial statements
- Lifecore Biomedical, Inc. \de\ key metrics
- Lifecore Biomedical, Inc. \de\ health scores and style box
- Lifecore Biomedical, Inc. \de\ earnings
- Lifecore Biomedical, Inc. \de\ dividends
- Lifecore Biomedical, Inc. \de\ valuation
- Lifecore Biomedical, Inc. \de\ ownership and insiders
- Lifecore Biomedical, Inc. \de\ peers
Figures from Lifecore Biomedical, Inc. \de\'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.